These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30062956)

  • 1. Epigenetic Drug Therapy in the Treatment of Colorectal Cancer.
    Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Seifi S; Parizadeh SMR; Moetamani-Ahmadi M; Hassanian SM; Khazaei M; Ghayour-Mobarhan M; Ferns GA; Avan A
    Curr Pharm Des; 2018; 24(23):2701-2709. PubMed ID: 30062956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic therapy for colorectal cancer.
    Vaish V; Khare T; Verma M; Khare S
    Methods Mol Biol; 2015; 1238():771-82. PubMed ID: 25421691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.
    Weisenberger DJ; Liang G; Lenz HJ
    Oncogene; 2018 Feb; 37(5):566-577. PubMed ID: 28991233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of epigenetic therapies in colorectal cancer.
    Baretti M; Azad NS
    Curr Probl Cancer; 2018 Nov; 42(6):530-547. PubMed ID: 29625794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance in colorectal cancer: An epigenetic overview.
    Luo M; Yang X; Chen HN; Nice EC; Huang C
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188623. PubMed ID: 34481016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
    Hosokawa M; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of epigenetics in colorectal cancer.
    Coppedè F
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):935-48. PubMed ID: 24871610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic-based therapy for colorectal cancer: Prospect and involved mechanisms.
    Rezapour S; Hosseinzadeh E; Marofi F; Hassanzadeh A
    J Cell Physiol; 2019 Nov; 234(11):19366-19383. PubMed ID: 31020647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Coppedè F; Lopomo A; Spisni R; Migliore L
    World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
    Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E
    Drug Resist Updat; 2011 Dec; 14(6):280-96. PubMed ID: 21955833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic Modifiers and Their Potential Application in Colorectal Cancer Diagnosis and Therapy.
    Shinde S; Saxena S; Dixit V; Tiwari AK; Vishvakarma NK; Shukla D
    Crit Rev Oncog; 2020; 25(2):95-109. PubMed ID: 33389860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic biomarkers in colorectal cancer diagnostics.
    Rawson JB; Bapat B
    Expert Rev Mol Diagn; 2012 Jun; 12(5):499-509. PubMed ID: 22702366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic biomarkers in colorectal cancer: premises and prospects.
    Zamani M; Hosseini SV; Mokarram P
    Biomarkers; 2018 Mar; 23(2):105-114. PubMed ID: 27788596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics of colorectal cancer.
    Migheli F; Migliore L
    Clin Genet; 2012 Apr; 81(4):312-8. PubMed ID: 22263639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
    Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
    Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation.
    Coppedè F
    Cancer Lett; 2014 Jan; 342(2):238-47. PubMed ID: 22202641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent clinical prognostic value of histone modifications in colorectal cancer.
    Goossens-Beumer IJ; Benard A; van Hoesel AQ; Zeestraten EC; Putter H; Böhringer S; Liefers GJ; Morreau H; van de Velde CJ; Kuppen PJ
    Transl Res; 2015 May; 165(5):578-88. PubMed ID: 25488396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics and its therapeutic potential in colorectal cancer.
    Oryani MA; Tavasoli A; Ghalavand MA; Ashtiani RZ; Rezaee A; Mahmoudi R; Golvari H; Owrangi S; Soleymani-Goloujeh M
    Epigenomics; 2022 Jun; 14(11):683-697. PubMed ID: 35473313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.